Axiom Investors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.77M | Buy |
56,115
+1,740
| +3% | +$54.8K | 0.01% | 124 |
|
|
2025
Q1 | $1.78M | Sell |
54,375
-15,521
| -22% | -$508K | 0.02% | 125 |
|
|
2024
Q4 | $2.53M | Buy |
69,896
+19,561
| +39% | +$707K | 0.02% | 120 |
|
|
2024
Q3 | $1.57M | Sell |
50,335
-4,525
| -8% | -$141K | 0.01% | 119 |
|
|
2024
Q2 | $1.47M | Buy |
54,860
+625
| +1% | +$16.7K | 0.01% | 122 |
|
|
2024
Q1 | $1.85M | Buy |
54,235
+5,780
| +12% | +$197K | 0.02% | 128 |
|
|
2023
Q4 | $1.4M | Buy |
48,455
+34,840
| +256% | +$1.01M | 0.01% | 129 |
|
|
2023
Q3 | $375K | Sell |
13,615
-10,285
| -43% | -$284K | 0.01% | 127 |
|
|
2023
Q2 | $718K | Sell |
23,900
-1,695
| -7% | -$51K | 0.01% | 121 |
|
|
2023
Q1 | $927K | Buy |
25,595
+5,355
| +26% | +$194K | 0.02% | 119 |
|
|
2022
Q4 | $722K | Buy |
+20,240
| New | +$722K | 0.01% | 120 |
|
|
2018
Q3 | – | Sell |
-57,230
| Closed | -$3.43M | – | 148 |
|
|
2018
Q2 | $3.43M | Buy |
57,230
+5,570
| +11% | +$333K | 0.1% | 103 |
|
|
2018
Q1 | $2.37M | Sell |
51,660
-5,030
| -9% | -$230K | 0.06% | 115 |
|
|
2017
Q4 | $2.26M | Sell |
56,690
-42,186
| -43% | -$1.68M | 0.06% | 114 |
|
|
2017
Q3 | $3.96M | Sell |
98,876
-72,955
| -42% | -$2.92M | 0.09% | 98 |
|
|
2017
Q2 | $7.41M | Buy |
171,831
+46,821
| +37% | +$2.02M | 0.18% | 72 |
|
|
2017
Q1 | $3.91M | Buy |
125,010
+25,146
| +25% | +$787K | 0.1% | 89 |
|
|
2016
Q4 | $2.52M | Buy |
+99,864
| New | +$2.52M | 0.07% | 113 |
|